



**Contact:**

Dr. Misha Plam  
AmideBio, LLC  
President & CEO  
misha.plam@amidebio.com  
(303) 641-3669  
<http://www.amidebio.com>

**AmideBio to present at TIDES conference on May 24, 2011**

**Boulder, CO December 31, 2010**

AmideBio, LLC announced today that Dr. Michael Stowell, Chief Technology Officer, AmideBio, LLC is going to present at TIDES conference:

**“Functional Differences between Synthetic and Recombinant Amyloid Peptides”**

“The AmideBio team investigated the functional differences between synthetic and AmideBio’s proprietary BioPure amyloid peptides using a combination of biophysical and cell assays. BioPure material has dramatically different properties than synthetically prepared material. The observed differences can be attributed to a combination of very minor N-1 and racemic peptide contaminants. These studies highlight the potential problems associated with synthetic peptides for both basic research and therapeutic applications.”

**About AmideBio, LLC**

AmideBio, based in Boulder, CO is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPure™), economical and incorporate environmentally sustainable practices. For more information please visit [www.AmideBio.com](http://www.AmideBio.com)

**About TIDES conference**

Oligonucleotide and Peptide® Technology and Product Development  
May 22-25, 2011 \* Hynes Convention Center \* Boston, MA  
*A Case Study Approach to Overcoming  
CMC Challenges of Drug Substance and Drug Product Development*

TIDES is the only event that covers CMC manufacturing of peptide and oligo therapeutics in an in-depth manner, with the largest showcase of providers of services and technology critical to the field, and a proven track record of attendance that guarantees you a superior networking opportunity. It also includes in-depth programming on oligonucleotides therapeutics discovery, peptide discovery and development, and nucleic acids technologies for molecular diagnostics. For a complete agenda please visit: [www.IBCLifeSciences/TIDES](http://www.IBCLifeSciences/TIDES)